Evidence map›Paper›PMID 39738586›Full record

ArticleScientific reports2024

Portable UV-C device to treat high flow of infectious aerosols generated during clinical respiratory care.

Richard Vincent, David Rapoport, Priti Balchandani, Joseph Borrello, Michael Schotsaert, Robert Karlicek, Gabriel Laghlali, Prajakta Warang, Seokchan Park, Gagandeep Singh and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Richard VincentDivision of General Internal Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Richard.Vincent@mountsinai.org.
David RapoportDivision of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Priti Balchandani *BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount Sinai, New York, USA.
Joseph BorrelloMount Sinai BioDesign, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
Michael SchotsaertDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Robert KarlicekRensselaer Polytechnic Institute, Troy, NY, USA.
Gabriel LaghlaliDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Prajakta WarangDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Seokchan ParkDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gagandeep SinghDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Isabella MorganMount Sinai BioDesign, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
James Paredes, Colorado Springs, CO, USA.
Raveen RathnasingheDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jacob WolfMount Sinai BioDesign, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
Adolfo García-Sastre *Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Funding

NIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6M
MSHS Translational Science HubUL1TR001433 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI WRIGHT, ROSALIND J · 2015 to 2019
$26.6M
Supplement: Adjuvant Screening for an inactivated SFTSV Vaccine75N93019C00046 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ADOLFO, GARCIA-SASTRE · 2019 to 2023
$9.1M
Combined adjuvant approaches for enhancement of SARS-CoV-2 vaccine efficacyR01AI160706 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2022 to 2025
$2.9M
7HP349, an oral integrin activator to augment effectiveness of pre-exposure influenza vaccinationR44AI176894 · NIAID · 7 HILLS PHARMA, LLC · PI DE, SIDDHARTHA, MARATHI, UPENDRA · 2023 to 2024
$1.9M
Experimental and natural SARS-CoV-2 infection of the human pancreasR01DK130425 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOMANN, DIRK, SCHOTSAERT, MICHAEL · 2021 to 2023
$1.3M
Impact of mucosal adjuvanted vaccines on virus transmission in preclinical animal models for SARS-CoV-2 and influenza virus infectionR21AI180874 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2024 to 2025
$472k
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunityR21AI176069 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCHOTSAERT, MICHAEL, WONG, PAMELA TINMOI · 2023 to 2024
$466k
CRIPT (Center for Research on Influenza Pathogenesis and Transmission), a NIH NIAID funded Center of Excellence for Influenza Research and Response (CEIRR, contract number 75N93021C00014),Korea Health Industry 914 Development Institute (KHIDI) for research under the Biomedical Global Talent Nurturing Program (HI22C2101).NCATS NIH HHS UL1 TR001433NIAID NIH HHS 75N93019C00046NIAID NIH HHS 75N93021C00014NIAID NIH HHS contract 75N93019C00046NIAID NIH HHS R01 AI160706NIAID NIH HHS R21 AI176069NIAID NIH HHS R21 AI180874NIAID NIH HHS R44 AI176894NIDDK NIH HHS R01 DK130425NIH/NCATS Grant 5UL1TR001433-05aNIH/NIAID R01AI160706NIH/NIDDK R01DK130425
6 · The paper itself

Abstract

Respiratory interventions including noninvasive ventilation, continuous positive airway pressure and high-flow nasal oxygen generated infectious aerosols may increase risk of airborne disease (SARS-CoV-2, influenza virus) transmission to healthcare workers. We developed and tested a prototype portable UV-C

Indexed as

AerosolsInfluenza A Virus, H1N1 SubtypeUltraviolet RaysCOVID-19DisinfectionHumansInfluenza, HumanSARS-CoV-2Aerosols

Identifiers

PMID39738586
PMCPMC11686185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.